Investigating heterogeneity in cancer (v1)

  • Research type

    Research Study

  • Full title

    Investigating heterogeneity in cancer initiation, progression, and treatment response: a translational study.

  • IRAS ID

    370997

  • Contact name

    Richard Owen

  • Contact email

    richard.owen@ludwig.ox.ac.uk

  • Sponsor organisation

    University of Oxford

  • Duration of Study in the UK

    3 years, 1 months, 30 days

  • Research summary

    Cancer affects 50% of people in the UK. Whilst many advances have been made in cancer treatment, including the introduction of “immunotherapies” which harness the body’s immune system to destroy cancer cells, certain types and stages of cancer remain challenging to treat. Some patients respond more positively to different types of treatment than others, but we not fully understand the reasons behind this. Identifying and understanding these underlying factors is a priority in the cancer research space, as it would enable us to identify those cancer patients most likely to benefit from particular therapies and ensure that they have access to these treatments. It would also enable us to identify those patients unlikely to benefit, which could spare these patients from experiencing treatment-related toxicities without gaining any clinical benefit.
    Many clinical trials aim to explore new cancer therapies, and to determine the particular characteristics of those patients who are likely to respond well to treatment. For this, samples, including blood and tissue, are gifted by patients, which can be characterised using laboratory techniques at the molecular level. Through these analyses, we may be able to identify particular molecular “markers” which are present in patients who respond well, or not so well, to treatment. In the future, these markers could inform clinical teams as to which therapies are most suited to which patients. Ensuring that these samples can be fully analysed, and that the results of different trials can be compared and contrasted, is vital to be able to draw meaningful conclusions.
    In this translational research project, we aim to thoroughly characterise samples from individuals with precancerous conditions or cancer, some of whom received treatment as part of various clinical trials. This project will ensure that samples from complementary trials are fully analysed, in order to maximise insights into the factors underlying cancer initiation, progression and treatment response.

  • REC name

    Wales REC 6

  • REC reference

    26/WA/0220

  • Date of REC Opinion

    6 Aug 2026

  • REC opinion

    Favourable Opinion